IN THE CLAIMS

Please cancel claims 19 and 63 without prejudice or disclaimer. Please amend claim to read as follows:

Claims 1-43 (Canceled).

44. (Currently amended) A method of recovering stable Factor VIII/[[vWF]] von Willebrand Factor (vWF)-complex from a protein solution that also contains contaminating proteins, wherein the method comprises

binding the Factor VIII/vWF-complex contained in the protein solution to an anion exchanger;

selectively eluting the contaminating proteins with an eluting agent containing [[a]] an elution salt concentration of $\leq$ 200 mM and [[$CaCl_2$]] and a calcium salt, and

subsequently recovering Factor VIII/vWF-complex from the anion exchanger in the absence of calcium at [[a]] an elution salt concentration of between $\geq$ 200 and $\leq$ 400 mM.

45. (Previously presented) The method according to claim 44, wherein the contaminating proteins are plasma proteins.

46. (Previously presented) The method according to claim 45, wherein the plasma proteins are selected from the group consisting of Vitamin K-dependent Factors, plasma proteases, fibronectin and fibrinogen.

47. (Currently amended) The method according to claim 44, wherein the calcium salt is $CaCl_2$ and is contained in the eluting agent at a concentration of between 1 mM and 15 mM.

48. (Currently amended) The method according to claim [[44]] 47, wherein the $CaCl_2$ is contained in the eluting agent at a concentration of 10 mM.

49. (Previously presented) The method according to claim 44, wherein the eluting is carried out at a pH of 6.0 to 8.5.

50. (Previously presented) The method according to claim 44, wherein the eluting is carried out at a pH of 7.4.

51. (Previously presented) The method according to claim 44, wherein the elution salt contained in the eluting agent is NaCl.

52. (Previously presented) The method according to claim 44, wherein a Factor VIII/vWF-complex containing high-molecular vWF multimers is obtained, and the Factor VIII/vWF-complex is free from low-molecular vWF molecules and from vWF degradation products.

53. (Previously presented) The method according to claim 44, further comprising subjecting the Factor VIII/vWF-complex recovered from said anion exchanger to a further chromatographic step.

54. (Previously presented) The method according to claim 53, wherein the further chromatographic step is affinity chromatography.

55. (Previously presented) The method according to claim 54, wherein the affinity chromatography is heparin chromatography carried out with a heparin affinity carrier by binding the Factor VIII/vWF-complex from the protein solution to the heparin affinity carrier in a buffer system and recovering the Factor VIII/vWF-complex at [[a]] an elution salt concentration of between ≥ 200 and ≤ 300 mM.

56. (Currently amended) The method according to claim 55, wherein the heparin affinity carrier is selected from the group consisting of AF-Heparin Toyopearl® ~~(Tosohaas)~~ (synthetic, hydrophilic polymer of large pore size based on methacrylate) , Heparin EMD-~~Fraktogel~~Fractogel® (synthetic, hydrophilic polymer based on ethylene glycol, methacrylate and dimethyl acrylate) and Heparin-Sepharose Fast Flow® (containing natural dextran and agarose derivatives).

57. (Currently amended) A method of ~~recovering~~ providing a stable Factor VIII/[[vWF]] von Willebrand Factor (vWF)-complex comprising

subjecting Factor VIII or a Factor VIII/vWF-complex to a chromatographic treatment so as to provide a purified Factor VIII or Factor [[VIIII]] VIII/vWF-complex;

admixing a purified high-molecular fraction of vWF molecules to the purified Factor VIII or Factor VIII/vWF-complex so as to provide a stable Factor VIII/vWF-complex having a molar ratio of Factor VIII to vWF of between 0.01 and 100, wherein the high-molecular fraction of vWF molecules has a specific platelet agglutination activity of at least 50 U/mg vWF:Ag.

58. (Previously presented) The method according to claim 57, wherein the molar ratio of Factor VIII to vWF is between 0.05 and 1.

59. (Previously presented) The method according to claim 57, wherein the purified Factor VIII or Factor VIII/vWF-complex is recovered from a plasma fraction.

60. (Previously presented) The method according to claim 57, wherein the purified Factor VIII or Factor VIII/vWF-complex is obtained from a cell culture supernatant derived from transformed cells, and the cell culture supernatant is free from cells.

61. (Previously presented) The method according to claim 57, wherein the purified high-molecular fraction of vWF molecules contains plasmatic vWF.

62. (Previously presented) The method according to claim 57, wherein the purified high-molecular fraction of vWF molecules contains recombinant vWF.

63. (Canceled).